Low back pain remains a highly prevalent pathology engendering a tremendous socioeconomic burden. Low back pain is generally associated with intervertebral disc (IVD) degeneration, a process involving the deterioration of nucleus pulpous (NP) cells and IVD matrix. Scientific interest has directed efforts to restoring cell numbers as a strategy to enable IVD regeneration. Currently, mesenchymal stromal cells (MSCs) are being explored as cell therapy agents, due to their easy accessibility and differentiation potential. For enhancement of MSCs, growth factor supplementation is commonly applied to induce differentiation towards a chondrogenic (NP) cell phenotype. The wnt signaling pathways play a crucial role in chondrogenesis, nonetheless, literature appears to present controversies with regard to wnt3a and wnt5a for the induction of NP cells, chondrocytes, and MSCs. This review aims to summarize the reporting on wnt3a/wnt5a mediated NP cell differentiation, and to elucidate the mechanisms involved in wnt3a and wnt5a mediated chondrogenesis for potential application as cell therapy supplements for IVD regeneration. Our review suggests that wnt3a, subsequently replaced with a chondrogenic stimulating growth factor, can enhance the chondrogenic potential of MSCs in vitro. Contrariwise, wnt5a is suggested to play a role in maintaining cell potency of differentiated NP or chondrogenic cells.
INTRODUCTION
Low back pain (LBP) is a disorder presenting itself among all adult-ages 1 affecting an estimated 632 million people globally. 2 Contemporary treatments are primarily focused on pain relief with a lack of therapeutic strategies able to target the pathogenesis of LBP. A particular shortcoming, considering up to 15% LBP-patients do not respond to conservative treatment intervention and progress to chronic LBP. 3 The onset of LBP is generally associated with the progression of intervertebral disc (IVD) degeneration, a complex process involving a reduction in active cell numbers, tissue disorganization, and overall loss of the IVDs biomechanical features. Particularly, the loss of proteoglycans from the central nucleus pulposus (NP) and consequential deterioration of water-retention, limits the ability of the IVD to distribute complex loads on the spine. 4 In order to alleviate IVD degeneration-associated LBP, restoration of the IVD and its biomechanical features will prove crucial. Nevertheless, similar to other cartilage-based tissues, the IVD presents a challenging tissue to regenerate. 5 Due to the avascular nature of the IVD, the in situ environment presents a nutrition-poor, biochemically harsh environment that is restricted in endemic cell attraction, and overall dependent on relatively low cell numbers for matrix production.
signaling pathways and cell functions. Wnt11 and especially wnt5a are reported to be beneficial for chondrogenesis, however literature predominantly assesses their function within embryonic development. 16 On the contrary, Wnt7a and wnt14 are reported to inhibit or reverse chondrogenesis. 17, 18 Wnt3a, however, is particularly of interest due to numerous contradictions in the literature. 19, 20 Most studies tend to agree upon the positive regulatory effect of wnt3a on cell proliferation, 16, 21, 22 however, both wnt3a activation and inhibition have been reported to downregulate cartilage phenotypic markers, and reduce glycosaminoglycan (GAG) production. 13, 21 Interestingly, in combination with other growth factors; e.g., fibroblast growth factor (FGF), 22 transforming growth factor (TGF)-β, 23, 24 and bone morphogenetic protein (BMP) 25, 26 family, wnt3a appears to be beneficial for MSCs to adopt a chondrogenic phenotype in 2-dimensional, and 3-dimensional cultures. 23, 27 Whether wnt3a and wnt5a are in fact beneficial for chondrogenesis remains arguable, however, their presence in cartilage-based tissues is undisputable, raising interest on the potential induction capacity of wnt3a/wnt5a on the cartilage-based NP. Therefore, it is considered valuable to reach a consensus on wnt3a and wnt5a in chondrogenesis for regeneration of the IVD. This review aims to assess the trend in effects of wnt3a and wnt5a on cells with chondrogenic potency, particularly the response in potency, proliferation and induction of chondrogenic differentiation. Knowledge regarding the potential of wnt3a and wnt5a to stimulate NP cell induction could potentially provide new insights for (cell-) therapies enhancing IVD regeneration.
Wnt SIGNALING IN INTERVERTEBRAL DISC DEVELOPMENT
The 19 identified wnt ligands and their corresponding receptors 15 are pivotal for cellular development, function, and tissue homeostasis, in various tissues, including cartilage tissues 11, 12 such as the IVD. 28, 29 Specifically during early development, IVD cells are highly dependent on wnt signaling for appropriate development. 28, 29 During these early stages, high activity of wnt is predominantly observed in the annulus fibrosis (AF) and the endplate (EP), however, with maturation, the AF and EP present weakening in signaling activity, while wnt activity persists in the NP even at later stages of development. 28 The importance is underlined by in vivo experiments presenting induction of IVD degeneration by suppression of wnt signaling in mice. 30 Similarly, in vitro work demonstrated that both induction and interference of wnt induce articular chondrocyte differentiation, 13 and wnt activation in NP cells may result in cell senescence. 31, 32 In short, a balance of wnt signaling is crucial for maintaining cartilage homeostasis. Nevertheless, the exact regulatory mechanisms involved in wnt-mediated homeostasis remains poorly understood. This is partly due to the large number of receptor-types involved in reacting to wnt. 33 This process is further complicated by the involvement of two distinctively separate downstream pathways effectuated to establish a cellular response; i.e., canonical and noncanonical signaling.
CANONICAL Wnt SIGNALING
Wnt proteins can bind to the receptor complex consisting of Frizzled and the low-density lipoprotein receptor-related protein (LRP) 5/6, provided that both are expressed on the surface, forming a trimeric complex. 34 Activation leads to the recruitment of Dishevelled (Dsh) and Axin. Subsequently, the formed protein complex consisting of Axin, Adenomatous Polyposis Coli, and glycogen synthase kinase-3β (GSK-3) is not capable to partake in proteasome activation. As together with casein kinase 1α, this complex is responsible for the ubiquitination of β-catenin triggering its degeneration by proteasomes. 35 Absence of this complex disables degradation of β-catenin and instead accumulates and translocates to the nucleus. Here, it interacts with the transcription factors lymphoid enhancer binding factor/T-cell specific transcription factor, activating transcription of a variety of WNT target genes (Fig. 1 ).
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NONCANONICAL Wnt SIGNALING
The noncanonical signaling pathway is poorly understood compared to the well-studied canonical pathway, partly due to multiple agents and mechanisms being involved. 37 Where the canonical pathway has only a few key players, mainly involved in degradation of β-catenin, thus preventing interaction in the nucleus for transcription, the noncanonical pathway has multiple agents capable of initiating various subsequent processes which are relatively difficult to separate and study. In contrast to canonical signaling, noncanonical signaling is β-catenin independent and while wnt still requires binding to Frizzled, the coreceptor LRP 5/6 is not involved. 38 Interaction with Frizzled can lead to the activation of calcium/calmodulin-dependent kinase II (CamKII) and protein kinase C (PKC), 38 referred to as the wnt/calcium pathway. Noteworthy is that this pathway is found to inhibit canonical signaling. 39 Additionally, in the planar cell polarity (PCP) pathway, Dsh is activated which regulates a variety of signaling cascades, for example activation of Rac, which in turn activates c-Jun N-terminal kinase (JNK). Additionally, Dsh activates Rho through Daam1 activating e.g., Rho-kinase and Profilin. 39 These processes are suggested to play a crucial role in cytoskeletal organization and cell adhesion as these are linked to actin polymerization. 39 Lastly, in the wnt/ leading to crosstalk with the PCP and wnt/calcium pathway (Fig. 2) . Possible crosstalk within noncanonical signaling and canonical signaling, together with the many agents involved, causes the exact mechanisms surrounding these pathways to remain ambiguous.
Wnt LIGANDS IN CHONDROGENESIS
In terms of chondrogenesis, wnts can be described on the ability to regulate chondrogenic (de-)differentiation or hypertrophy. Most wnts have been studied thoroughly and are suggested to have clear effects on chondrogenesis. For example, wnt1, wnt4, wnt7a, wnt8, and wnt9a have been determined to inhibit chondrogenic differentiation. 19, 20 Wnt5a and wnt5b however, have been reported to induce chondrogenesis in developmental stages, whereas it inhibits chondrogenesis in later stages. 19, 20 The different effects during the various stages of development, causes the use of wnt5a and wnt5b in chondrogenic differentiation to remain ambiguous. Additionally, discrepancies in the literature on the chondrogenic effects of wnt3a, lead to
Fig. 2.
Signaling options initiated via wnt5a and the concluded outcome. Wnt5a can bind to receptor tyrosine kinase-like orphan receptor 2 (ROR2) which leads to the activation of c-Jun N-terminal kinase (JNK). ROR2 is also able to act as a coreceptor with Frizzled. Wnt5a can bind to Frizzled and ROR2 leading to the activation of calcium/calmodulin-dependent kinase II (CamKII) and protein kinase C (PKC). Dishevelled (Dsh) is also able to activate Rac which in turn induces JNK. Moreover, Dsh can interact with DAAM1 to activate Rho which in turn activates ROCK. The last pathway is through activation of adenylate cyclase (AC), which triggers cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) inhibiting the transcription factor NFATc1. This figure is a hypothetical estimation based on the literature discussed in this paper. Chon, chondrocytes; NPC, nucleus progenitor cell; MSC, mesenchymal stromal cell; PG, proteoglycan.
www.e-neurospine.org 23 reviews reporting contradictory conclusions, stating that wnt3a stimulates, 20 but also inhibits chondrogenic differentiation. 19 Another unusual characteristic of wnt3a is the capacity to activate both the canonical and noncanonical pathway 21, 44 which might partly help explain the contradictory reporting on wnt3a effects. This theory is supported by studies reporting that downregulation of canonical signaling by e.g., dickkopf-related protein 1 (DKK1) as LRP antagonist, is able to partly rescue wnt3a-induced loss of chondrogenesis. 45 Similarly by applying a GSK-3 inhibitor could alleviate wnt3a repression of chondrogenesis, and was found to effectuate its regulation via β-catenin pathway. 46 Furthermore, decreased proteoglycan production caused by wnt3a could be recovered after addition of DKK3. 47 Recently, a knockdown of exotosin-1 (Ext1), encoding a glycosyltranserase required for heparin sulfate (HS) chain elongation in HS-proteoglycan biosynthesis, was determined to downregulate canonical wnt signaling activation but upregulate markers for chondrogenesis. 48 The collective data appears to suggest that canonical signaling is responsible for wnt3a mediated inhibition of chondrogenesis. However, separate wnt3a studies that blocked noncanonical signaling by specific inhibition of the Ca2+/CaMKII pathway, were likewise able to rescue wnt3a induced loss of the chondrocyte phenotype. 13, 21 Expression of COL2A1, aggrecan, and SOX9 all improved after Ca2+/CaMKII inhibition at higher rates than DKK1-mediated inhibition of canonical signaling. 13, 21 Besides the CaMKII pathway, the PCP pathway has also been demonstrated to mediate dedifferentiation in chondrocytes. JNK inhibition resulted in the rescue of wnt3a downregulated chondrogenic markers SOX9 and CO-L2A1. 49 Therefore, the distinct effects on chondrogenesis by wnt3a cannot directly be related to the pathway that is activated. However, the balance of canonical and noncanonical signaling appears essential as both stimulation and inhibition of one specific pathway appear disadvantageous for chondrogenesis.
Wnt3a HAS A CELL TYPE DEPENDENT INFLUENCE ON CHONDROGENESIS WHEREAS THE INFLUENCE OF Wnt5a APPEARS HOMOGENOUS
Although wnt3a is capable of signaling through both canonical and noncanonical signaling, 21, 44 the contradictory effects on chondrogenesis of wnt3a appears not to be dependent on which specific pathway is activated ( Fig. 1) . Therefore, the next question was whether the role of wnt3a in chondrogenesis is cell type dependent. Our findings (Table 1 ) confirm the ability of wnt3a to both induce and inhibit chondrogenesis, and indicates a cell type-specific response. In contrast, the response to wnt5a on chondrogenesis appears more homogeneous regarding cell types and supplementation methods (Table 1) . Next, we review the differences in outcomes between cell types in response to being subjected to either wnt3a or wnt5a.
NUCLEUS PULPOSUS CELLS
NP cells subjected to an abundance of WNT3A via (lentiviral-mediated) overexpression 16, 31, 32 or wnt3a supplementation via medium 31 are not affected in chondrogenic marker expression nor proteoglycan production. However, proliferation was shown to be enhanced with overexpression of WNT3A in human NP cells relative to WNT5a/WNT11 overexpression and non-induced NP cells. 16 Solely upregulation of wnt/β-catenin signaling caused no proliferation in rat-derived NP cells however, cell viability was determined to decrease with 50%. 32 Moreover, wnt/β-catenin signaling was demonstrated to regulate tumor necrosis factor (TNF)-α, 47 linking it to IVD degeneration, 50, 51 suggesting once more that the balance of canonical and noncanonical signaling is crucial for the outcome of wnt3a treatment. Interestingly, upregulation of the PKC pathway, of the noncanonical signaling pathway, induced cell proliferation in rat NP cells. 52 However, this phenomenon has not been studied in human NP cells. Studies conducted on human cells primarily focus on the canonical pathway, 53 in which contradictive results are obtained as specific downregulation of wnt/β-catenin signaling leads to NP cell apoptosis, 54 while activation of wnt/β-catenin signaling is also reported to result in NP cell apoptosis. 55 Canonical and noncanonical signaling appears to have crosstalk leading to a chain of reactions which are likely challenging to control. One hypothesis is that the balance of canonical and noncanonical signaling is essential for inducing NP cell differentiation, thus making it challenging to regulate wnt3a with a specific inhibitor or stimulator of either canonical or noncanonical signaling. Adding to the complexity of wnt3a, other agents such as BMP2 and TGF-β are found to activate wnt/β-catenin 56 signaling whereas overexpression of R-Smad, an intracellular signaling protein downstream of the BMP/TGF signaling pathway, inhibits wnt/β-catenin signaling. 31 Crosstalk of the BMP/ TGF-β family with wnt signaling is hypothesized to potentially control the balance of canonical and noncanonical signaling utilizing downstream signaling proteins like Smad. 31 Overexpression of WNT5A in human NP cells results, in contrast to WNT3A, in the reduction of proliferation compared to 24 www.e-neurospine.org 16 However, WNT5A overexpression is beneficial for the redifferentiation of NP cells as shown by the upregulation of specific NP cell markers such as PAX1 and FOXF1 and matrix genes COL2A1 and ACAN. 16 Moreover, the GAG/collagen II ratio, as a specific marker for healthy NP matrix (i.e., ~25:1 compared to a ratio of ~2:1 in juvenile cartilage 57 ), is significantly increased after WNT5A overexpression 16 and lost upon lentiviral knockdown of WNT5A, as is the upregulation of the NP cell markers and matrix genes.
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CHONDROCYTES
In chondrocytes, the effects of wnt3a are described repeatedly to stimulate chondrogenic dedifferentiation. 13, 27, [45] [46] [47] [48] [49] [58] [59] [60] The origin of the chondrocytes studied ranged from humans, large animals (i.e., bovine), to smaller animals (i.e., rat or chicken). Despite the differences in the supplementation method and the origin of the cells, all articles reported either a loss of chondrogenic gene marker expression, decreased proteoglycan production or a combination of these. However, addition of wnt3a appears to upregulate proliferation rate. 13, 58 This could suggest that wnt3a inhibits the maturation state of chondrogenesis and instead gives rise to a more potent cell phenotype. Wnt5a initially appears to be described with conflicting results in available literature, as wnt5a is shown to both promote and inhibit chondrocyte differentiation. 45, 61 The discrepancy appears to originate from cellular differentiation stage at which wnt5a is introduced. Particularly, wnt5a appears to induce chondrogenic differentiation in early stages of differentiation whereas it inhibits maturation and inhibits hypertrophy in the end stages of chondrogenesis. 45, 61 Contrariwise, blocking wnt5a decreased early chondrocyte differentiation but enhanced hypertrophy. 61 Noteworthy, the beneficial effects of wnt5a treatment are quite temporarily as enhanced chondrogenic markers expression was observed following wnt5a stimulation, which thereafter rapidly decreases. 61 Wnt5a is described to eventually stimulate enzymatic cartilage matrix degradation, inhibiting chondrogenesis. 45, 62 These results demonstrate the stage-dependent influence of wnt5a in chondrocytes. In vivo, similar observations have been made. 12, 45, 63 Wnt5a is found to have a significant role in chondrogenesis where it follows a proximodistal gradient in the mesoderm of the developing limb. 64 Ectopically expression of WNT5A in chicken limb buds, results in malformation of the tissue i.e., reduced bone size and presenting a less matured phenotype.
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EMBRYONIC STEM CELLS
In ESCs, wnt3a is mainly reported to benefit expansion to generate a large number of chondrogenic potent cells. Moreover, wnt3a is stated to inhibit chondrogenesis, and instead induces cells to adopt a more immature phenotype. 26, 65 Work by
Tanaka et al. 65 demonstrated that wnt3a, especially in combination with the BMP4 inhibitor noggin (NOG), can generate lateral plate mesoderm phenotypes capable of differentiating towards a chondrogenic phenotype. Interestingly, Waese and Stanford 26 found that when first supplying the cells with BMP4 for 5 days and thereafter replacing BMP4 for wnt3a, chondrogenic potential could be optimized. Thus, suggesting that BMP4 is beneficial at the onset of differentiation while wnt3a acts as a late inducer of chondrogenesis, indicating that the crosstalk of BMP4 and wnt3a might be crucial for the chondrogenic differentiation of ESCs.
No work was identified that applied wnt5a directly onto ESC for chondrogenic differentiation. However, Gibson and colleagues 66 have applied wnt5a supplementation with pellet cultures of ESCs that were predifferentiated to take on a MSC phenotype. Similar effects were reported by wnt5a as observed with wnt3a 66 viz. promoting chondrogenesis and limiting hypertrophy. Chondrogenic markers SOX9 and COL2A1 increased whereas the expression of hypertrophy markers; COL10A1 and ALP, decreased. In the same study, 66 the effect of BMP2 was found to upregulate early chondrogenic markers and proteoglycan production, attaining higher ratios than wnt5a. However, BMP2 also significantly increased expression of hypertrophic markers. The sequential treatment of BMP2 and wnt5a showed beneficial for inducing articular chondrocyte-like phenotypes, constituting initial chondrogenic induction via BMP2, followed by wnt5a supplementation on the fifth day to maintain the chondrogenic phenotype and preventing hypertrophy.
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MESENCHYMAL STEM CELLS
In MSCs, the chondrogenic effect of wnt3a is found to be the most variable across different studies ( Table 1 ). The reporting agrees on the effects regarding the induction of proliferation. In all identified cases reporting on cell growth, wnt3a treatment lead to significantly higher proliferation rates. [21] [22] [23] 67 Nevertheless, wnt3a does appear to have a negative effect on chondrogenesis according to two independent reports 21,49 applying either overexpression in rat MSCs 21 or supplementation in chicken embryo limb-bud MSCs. 49 www.e-neurospine.org 29
Two studies 24, 68 measuring WNT3A expression in MSCs after TGF-β3-mediated chondrogenesis on different substrates, showed opposing results as the samples with the highest chondrogenic potential were determined to have the lowest relative expression of WNT3A according to Hsu and Huang 68 or highest WN-T3A expression in the paper of Pei et al. 24 in pellets with the most prominent chondrogenic characteristics. However, due to the differences in culture substrates and cell sourcing, these studies are not directly comparable. Three papers 22, 23, 25 on wnt3a mediated induction of MSCs concluded an increase in chondrogenic potential caused by wnt3a when expanded in combination or subsequently replaced by a chondrogenic stimulating growth factor. Narcisi et al. 22 found that dual supplementation of wnt3a and FGF2 during expansion significantly enhanced the chondrogenic potential of MSCs. Contrarily, supplementation of wnt3a without FGF2, did not significantly stimulate GAG production nor COL2 expression relative to non-induced MSCs. Similarly, MSC expansion with wnt3a followed by subsequent TGF-β1 stimulation similarly resulted in significant increased GAG deposition, 23 however, addition of FGF2 during wnt3a stimulated monolayer culture abolished these beneficial effects. In the research of Fischer et al., 25 overexpression of WNT3A in combination with BMP2 in murine embryo derived MSCs, resulted in significantly higher proteoglycan production. 25 From these observations we hypothesize that wnt3a is not directly able to induce a chondrogenic phenotype, but rather has the capacity to enhance chondrogenic potential, stimulating chondrogenesis induced by other growth factors in human MSCs. As wnt3a appears to increase proliferation (Table 1 ) and reduce hypertrophic markers 22 it is possible that wnt3a maintains cell potency and thus enables MSCs to preserve a higher chondrogenic potential. When used during expansion and subsequently replaced with chondrogenic growth factor, wnt3a could reinforce chondrogenic potential which could be a strategy to optimize chondrogenic differentiation of MSCs. Indications of the significance of wnt5a in chondrogenic MSC differentiation can be derived from Dickinson et al. 69 Here, ROR2
was identified as a cell surface marker on MSCs with an enhanced chondrogenic potential. After separation ROR2 positive MSCs were embedded in a collagen sponge and implanted in a prepared defect within the medial femoral condyle of sheep. After remaining in vivo for 3 months, the implants with increased ROR2 expression contained higher expression of chondrogenic markers. 69 Also, during TGF-β3 induced chondrogenic differentiation, wnt5a levels significantly increased, reaching higher levels than the control group of articular chondrocytes. A significant downregulation followed over time, while the expression in articular chondrocytes remained low, 70 further emphasizing the role of wnt5a in early chondrogenic differentiation. Finally, Hsu and Huang 68 examined MSCs seeded on different substrates and their ability to induce chondrogenic differentiation, and showed that samples presenting highest chondrogenic potency (chitosan grafted with higher densities of hyaluronan) presented a significantly higher expression of WNT5A. Overall, the response of MSCs to wnt5a treatment appears relatively homogeneous. As discussed, wnt5a appears stimulatory towards chondrogenesis (specifically in early stages) while appearing to inhibit maturation and hypertrophy. 66 This is further emphasized by an in vivo study overexpressing WNT5A in chicken wing bud MSCs, resulting in a 1.5-fold enhanced alcian blue staining and increase in the number of nodules, whereas the activity levels of the maturation marker ALP, did not detectably change. 71 From this collection of data, wnt5a appears to play a crucial role in inducing chondrogenesis and is able to inhibit hypertrophic chondrogenesis.
Wnt3a AND Wnt5a AS TOOLS FOR REGENERATION OF THE INTERVERTEBRAL DISC
As mentioned previously, interest has been paid to the potential of growth factors 72, 73 and cells 7, 9 for regeneration of the IVD.
Wnt3a and wnt5a are crucial factors for the maintenance and induction of cells to a chondrogenic phenotype and thus hold promise as tools in treatment of IVD degeneration. For the establishment of IVD regeneration via cell therapy, ideally NP cells are employed due to their intrinsic capacity to survive and thrive within the IVD. 74 Nevertheless, IVD cells are commonly derived from compromised tissue sources presenting low cellular yield and reduced cell potency. 10, 74, 75 Moreover, standard expansion of NP cells in vitro further reduces their overall potency. 75, 76 From our current review, however, neither wnt3a nor wnt5a seem to have a clear beneficial effect on NP cell proliferation induction to enhance cell numbers, maintain overall potency, or induce a chondrogenic phenotype in vitro (Figs. 3A,  4A ). Their effect in vivo remains largely undetermined. Li et al. 77 studied the effect of wnt5a on rat induced disc degeneration and found that administration of wnt5a could enhance the rate of aggrecan and type II collagen producing cells, as well as presenting enhanced magnetic resonance imaging index maintenance. Moreover, the authors nicely presented the ability of 30 www.e-neurospine.org wnt 5a to limit IVD inflammation by inhibiting the action of TNFα. Nevertheless, in vivo application does require caution, as multiple reports have presented the ability of wnt5a to induce or support osteogenesis, [78] [79] [80] tissue-fibrosus, 81, 82 and M2 polarization of macrophages. 83 Similarly, wnt3a has been associated with the progression of a variety of tumors. 84 On the contrary, wnt3a and wnt5a influence on chondrocytes presents a more apparent effect. Chondrocytes resemble NP cells, as both reside in avascular tissues of which the function is to distribute and transfer biomechanical pressure, 85 appointing chondrocytes as a potential alternative to NP cells. Opposingly, chondrocytes do present a lower ratio of PG vs collagen production 57 and are endemically developed to adapt to distinctly different biomechanical forces as suggested by the matrix organization in articular cartilage. Moreover, altering these behavior facets of mature cells might be particularly challenging. From our review the applications of wnts as a method to enhance chondrocytes regenerative capacity is not suggested to be a viable option. Wnt3a, although able to enhance cell proliferation, evidently has a negative impact on the chondrogenic features of the cells (Fig. 3B) . Although, wnt5a does not seem to impact cell proliferation, it does reduce its chondrogenic phenotype (Fig. 4B ). As such, preconditioning with either of these ligands appears delicate and stimulating chondrocytes with either wnt3a or wnt5a is likely not to be efficient to enhance the capacity of chondrocytes for cellular products towards IVD repair.
www.e-neurospine.org 31 However, wnt3a and wnt5a under appropriate conditions appear to hold promise for the induction of MSC differentiation to adopt a more chondrogenic phenotype. MSCs have distinct advantages to differentiated NP cells or chondrocytes, such as easy accessibility, a high cell potency, 86 and immunomodulatory properties. 87 Moreover, MSCs possess multipotent differentiation capabilities, including towards NP cell-like phenotypes, [88] [89] [90] although, the precise nature of these chondrogenic MSCs remains ill-defined. Moreover, it remains undetermined whether the primary effect of transplanted cells is their immunomodulatory effects, endemic cell reactivation, active contribution to matrix production, or a combination thereof. [91] [92] [93] Nonetheless,
MSCs are being explored in clinical setting, and their primary data suggest MSC transplantation to be safe and able to provoke clinical improvements. 7 In order to enhance the potency of MSCs to succeed in the IVD, multiple studies have explored the potential of preconditioning cells prior to IVD transplantation. 94 Our review suggests that sole supplementation of wnt3a
to MSCs consistently enhanced their proliferative capacity. However, wnt3a presented a relative negative effect on chondrogenic characteristics. Interestingly, however, is the capacity of wnt3a to maintain (chondrogenic) potency of MSCs in culture, which potentially enables enhanced chondrogenic differentiation upon the subsequent or combined supplementation of an additional (chondrogenic) growth factor (Fig. 3C ). On the other hand, the positive relation of wnt5a on chondrogenesis is homogeneously supported by our identified papers. 19, 20 Moreover, data suggest wnt5a interferes with hypertrophic maturation (Fig. 4C) . 71 Although, verification is required on the ability of wnt5a and wnt3a to optimize MSC-based cell therapy products for the IVD regeneration, current in vitro results do suggest beneficial effects with regard to maintaining MSC potency by wnt3a or stimulating chondrogenic features by wnt5a.
CONCLUDING REMARKS
In this review, we present the role of wnt3a and wnt5a as potential chondrogenic stimulators and for the potential use as NP cell and MSC inducers. Wnt3a and wnt5a are each found able to support NP cell induction in their respective ways, however, their effect appears highly context dependent and varies dependent cell type. Data suggest that the application of wnt3a primarily has the ability to enhance proliferation and maintain potency. Although, undesirable loss in chondrogenesis is observed in chondrogenic cells, including NP cells, wnt3a appears to be able to prolong MSC chondrogenic potency with extend-32 www.e-neurospine.org ed culture. On the contrary, wnt5a appears to restrict NP cell and chondrocytes chondrogenic features, while for MSCs it induces early chondrogenic stimulation. Although preconditioning of MSCs is actively being explored 88, 95, 96 and preculturing of MSCs under hypoxic conditions proved to be safe and promising in human clinical trials against IVD degeneration, 97 more research is required to confirm the beneficial effects of wnt3a and wnt5a as NP cell inducers, and the competence of these stimulated cells to thrive in a degenerative IVD. Elucidation of the regulatory pathways involved in wnt-responses could provide new insights and targets for tackling IVD degeneration and producing regenerative strategies for IVD repair. Once a thorough understanding of the effect of wnt3a and wnt5a treated cells in vivo is achieved, the use of these growth factors may serve as a valuable tool as chondrogenic stimulators for NP cell induction.
